权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MOLECULAR THERAPEUTICS RESEARCH PROGRAM

分子治疗研究计划

基本信息

批准号：
7944597
负责人：
ALAN R EASTMAN
金额：
$ 5.43万
依托单位：
DARTMOUTH COLLEGE
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-21 至 2013-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7944597
关键词：
Apoptosis Apoptotic Area Basic Science Biological Monitoring Biopsy Cancer Center Cancer Center Support Grant Cancer Patient Cell Cycle Regulation Cisplatin Clinical Clinical Trials Collaborations Development Diagnosis Disease Disease Outcome Drug effect disorder Faculty Fatty-acid synthase Fostering Funding Goals Gossypium Investigation MCL1 protein Malignant neoplasm of pancreas Molecular Molecular Target Neoadjuvant Therapy New Agents Non-Small-Cell Lung Carcinoma Outcome Paper Pathway interactions Pharmaceutical Preparations Phase Phase I Clinical Trials Productivity Proteasome Inhibitor Proteins Publications Research Research Personnel Role Series Signal Transduction Testing Therapeutic Therapeutic Clinical Trial Therapeutic Human Experimentation Translating Translations Tumor Tissue cancer therapy clinical application drug discovery expectation improved inhibitor/antagonist malignant breast neoplasm member new technology novel novel strategies novel therapeutics programs smoothened signaling pathway treatment strategy tumor tumor growth tumor progression

项目摘要

The goal of the Molecular Therapeutics Program (MT) is to foster the exchange of ideas, cooperation, and collaboration leading to translation of basic research focused on the identification and development of novel therapeutics into clinical applications, and to use basic research to answer clinical questions related to improving the treatment of cancer. The MT Program provides a forum for discussion and advancement of new developments in target identification, drug discovery, and mechanisms of drug action, and for translating these approaches into novel correlative and therapeutic clinical trials. The Program currently has 27 members from 7 departments and $8.2 millon in total funding, of which almost $4 million (61%) is from the NCI. The productivity over the past 5 years exceeds 240 papers, including 16% intra-program and 26% interprogram collaborative publications. Eighteen Program faculty participated in intra-program and 18 in interprogram collaborations, providing strong evidence of a highly interactive research program. Recent programmatic highlights include evidence for the role of the fatty acid synthase pathway as an independent marker of breast cancer progression, and the recognition that it can be targeted to suppress tumor growth. Other molecular targets under investigation include proteins in the Hedgehog signaling pathway, which is frequently activated in non-small cell lung cancer. New agents such as novel proteasome inhibitors and suppressors of the anti-apoptotic proteins Mcl-1 and Bcl-2 are under investigation, with the expectation of bringing these drugs to clinical trial at Morris Cotton Cancer Center. Novel treatment strategies developed in the MT Program that have been translated into Phase I clinical trials include the combination of cisplatin plus the Chk1 inhibitor UCN-01. In is study serial tumor biopsies were used to monitor biological activity in tumor tissue. Other investigators have developed novel technologies and complementary approaches to define predictive markers and therapeutic strategies, and an important goal of the MT Program is to test these ideas in correlative and therapeutic clinical trials at the NCCC. Also worthy of particular notice is a series of Phase I and II clinical trials in pancreatic cancer using chemoradiation in the neoadjuvant setting that has identified a promising treatment approach in this highly aggressive disease and demonstrates the Program's impact on disease outcome in cancer patients.

分子治疗学项目（MT）的目标是促进思想交流、合作和创新